Related Experiment Video

Updated: May 5, 2026

Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model
10:23

Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model

Published on: November 13, 2012

13.1K

Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3

Ethan V Abel1, Kevin J Basile, Curtis H Kugel

  • 1Department of Cancer Biology and Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.

The Journal of Clinical Investigation
|April 2, 2013
PubMed

Insights

Melanoma develops resistance to targeted therapies via ERBB3 upregulation by FOXD3. Combining ERBB2 and RAF inhibitors overcomes this resistance, improving melanoma treatment outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Adaptive resistance mechanisms to targeted therapies in melanoma are not fully understood.
  • RAF inhibitors are a key treatment for melanoma, but resistance limits their long-term efficacy.

Purpose of the Study:

  • To elucidate the molecular mechanisms of adaptive resistance to RAF inhibitors in melanoma.
  • To investigate the role of ERBB3 signaling in melanoma resistance.
  • To evaluate combination therapy targeting ERBB3 and RAF pathways.

Main Methods:

  • Chromatin immunoprecipitation sequencing (ChIP-seq) combined with gene expression profiling.
  • In vitro studies using melanoma cell lines.
  • In vivo studies using mouse xenograft models.

Main Results:

  • FOXD3 transcription factor upregulates ERBB3, conferring resistance to RAF inhibitors in melanoma.
  • Enhanced ERBB3 signaling promotes resistance in cell lines and xenograft models.
  • Combination therapy with lapatinib (ERBB2 inhibitor) and PLX4720 (RAF inhibitor) reduced tumor burden and delayed regrowth in vivo.

Conclusions:

  • Upregulated ERBB3 signaling is a key adaptive resistance mechanism to RAF inhibitors in melanoma.
  • Co-targeting ERBB3/ERBB2 and RAF pathways offers a promising strategy to enhance therapeutic efficacy and duration.
  • This approach may improve clinical outcomes for melanoma patients receiving targeted therapy.

More Related Videos

A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

18.1K
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

8.6K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.3K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
5.2K